Yes, duloxetine can cause decreased appetite.
Decreased appetite is a well-established adverse effect of duloxetine, documented across multiple clinical guidelines and FDA labeling. This occurs as a class effect of serotonin-norepinephrine reuptake inhibitors (SNRIs), though the clinical significance varies by patient population and treatment duration.
Evidence from Guidelines and FDA Labeling
The most authoritative evidence comes from the FDA drug label 1, which explicitly lists decreased appetite as one of the most common adverse reactions (≥5% in duloxetine-treated patients and at least twice the incidence of placebo). In pediatric trials specifically, decreased appetite occurred in 10% of duloxetine-treated patients versus 5% of placebo patients 1.
The 2020 AACAP clinical practice guideline 2 confirms that adverse effects of SNRIs including duloxetine "can include (but are not limited to)... decreased appetite, and weight loss." This guideline emphasizes that medical monitoring should include height and weight for all SNRI-treated patients.
The 2021 AGA clinical practice update 3 on gut-brain disorders lists reduced appetite among the common side effects of duloxetine when used as a neuromodulator, alongside nausea, sedation, and headache.
Clinical Context and Time Course
The pattern of appetite changes with duloxetine follows a predictable trajectory:
Short-term (8-9 weeks): Research shows duloxetine-treated patients experience mean weight loss of -0.5 kg compared to +0.2 kg gain with placebo 4. This initial period is when decreased appetite is most pronounced.
Long-term (>34 weeks): The appetite suppression typically diminishes, with patients showing modest weight gain (0.7-1.1 kg) during extended treatment 4.
In pediatric populations, the effect is more clinically significant. The FDA label 1 reports that 16% of duloxetine-treated children experienced clinically significant weight loss (≥3.5%) compared to 6% on placebo, necessitating regular weight and height monitoring.
Comparison to Other Medications
When compared to pregabalin in diabetic neuropathy trials 5, decreased appetite was more frequent with duloxetine than pregabalin, establishing this as a distinguishing adverse effect profile. The 2010 Mayo Clinic neuropathic pain guidelines 6 note that nausea is the most common adverse effect of duloxetine, with decreased appetite being a related gastrointestinal manifestation.
Clinical Monitoring Recommendations
Monitor weight at baseline and regularly during treatment, particularly in:
- Pediatric patients (7-17 years): Weight should be checked at each visit, with particular attention to those experiencing ≥3.5% weight loss 1
- Elderly patients: Who may be more vulnerable to nutritional compromise
- Patients with comorbid conditions affecting nutritional status
The decreased appetite typically presents alongside other gastrointestinal effects like nausea (18% in pediatric trials) 1. Starting at 30 mg daily for one week before increasing to 60 mg can reduce these gastrointestinal side effects 6.
Important Caveats
While decreased appetite is common, it should be distinguished from more serious complications. The FDA label 1 warns that in rare cases, duloxetine can cause hepatic failure presenting with abdominal pain, which could be confused with appetite-related symptoms. Additionally, in elderly patients, decreased appetite combined with other symptoms like nausea and malaise could indicate drug-induced hyponatremia/SIADH 7, requiring sodium level monitoring.
The appetite suppression is generally mild to moderate and transient 8, but the cumulative effect on nutritional status warrants clinical attention, especially in vulnerable populations.